Protection in Glutamate-Induced Neurotoxicity by Imidazoline Receptor Agonist Moxonidine

REFERENCES

• Albright T. D., Jessell T. M., Kandel E. R., Poster M. I. Neural science: A century of progress and the mysteries that remain. Cell 2000; 18: 1–55
   Google Scholar
• Aroor A. R., Shukla S. D. MAP kinase signaling in diverse effects of ethanol. Life Science 2004; 74: 2339–2364
   PubMedGoogle Scholar
• Arundine M., Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cellular and Molecular Life Sciences 2004; 61: 657–668
   PubMed Web of Science ®Google Scholar
• Berkman M. Z., Zirh T. A., Berkman K., Pamir M. N. Tizanidine is an effective agent in the prevention of focal cerebral ischemia in rats: An experimental study. Surgical Neurology 1998; 50: 264–271
   PubMedGoogle Scholar
• Bousquet P., Feldman J., Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs; differences between catecholamines and imidazolines. The Journal of Pharmacology and Experimental Therapeutics 1984; 230: 232–236
   PubMed Web of Science ®Google Scholar
• Chase T. N., Oh J. D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Annals of Neurology 2000; 47: 7–14
   Google Scholar
• Chen X., Lan X., Mo S., Qin J., Li W., Liu P., et al. p38 and ERK, but not JNK, are involved in copper-induced apoptosis in cultured cerebellar granule neurons. Biochemical and Biophysical Research Communications 2009; 379(4)944–948
   PubMedGoogle Scholar
• Choi D. W. Ionic dependence of glutamate neurotoxicity. The Journal of Neuroscience 1987; 7: 369–379
   PubMed Web of Science ®Google Scholar
• Choi S. H., Choi D. H., Lee J. J., Park M. S., Chun B. G. Imidazoline drugs stabilize lysosomes and inhibit oxidative cytotoxicity in astrocytes. Free Radical Biology & Medicine 2002; 32: 394–405
   PubMed Web of Science ®Google Scholar
• Coyle J. T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689–695
   PubMed Web of Science ®Google Scholar
• Csete K., Papp J. G. Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits. Journal of Cardiovascular Pharmacology 2000; 35: 417–421
   PubMedGoogle Scholar
• Eglen R. M., Hudson A. L., Kendall D. A., Nutt D. J., Morgan N. G., Wilson V. G., et al. Seeing through a glass darkly: Casting light on imidazoline ‘I’ sites. Trends in Pharmacological Sciences 1998; 19: 381–390
   PubMed Web of Science ®Google Scholar
• Feinstein D. L., Reis D. J., Regunathan S. Inhibition of astroglial nitric oxide synthase type 2 expression by idazoxan. Molecular Pharmacology 1999; 55: 304–308
   PubMedGoogle Scholar
• Fernandes A., Falcão A. S., Silva R. F., Brito M. A., Brites D. MAPKs are key players in mediating cytokine release and cell death induced by unconjugated bilirubin in cultured rat cortical astrocytes. European Journal of Neuroscience 2007; 25(4)1058–1068
   PubMedGoogle Scholar
• Garcia-Sevilla J. A., Escriba P. V., Guimon J. Imidazoline receptors and human brain disorders. Annals of the New York Academy of Sciences 1999; 21(881)392–409
   Google Scholar
• Gilad G. M., Salame K., Rabey J. M., Gilad V. H. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sciences 1996; 58: 41–46
   Web of Science ®Google Scholar
• Halaris A., Plietz J. Agmatine : Metabolic pathway and spectrum of activity in brain. CNS Drugs 2007; 21(11)885–900
   PubMed Web of Science ®Google Scholar
• Kemp J. A., McKernan R. M. NMDA receptor pathways as drug targets. Nature Neuroscience 2002; 5: 1039–1042
   PubMed Web of Science ®Google Scholar
• Klimaviciusa L., Safiulina D., Kaasik A., Klusa V., Zharkovsky A. The effects of glutamate receptor antagonists on cerebellar granule cell survival and development. Neurotoxicology 2008; 29(1)101–108
   PubMedGoogle Scholar
• Kostrzewa R. M. Evolution of neurotoxins: From research modalities to clinical realities. Current Protocols in Neuroscience 2009, Jan;Chapter 1:Unit 1.18
   PubMedGoogle Scholar
• Maiese K., Pek L., Berger S. B., Reis D. J. Reduction in focal cerebral ischemia by agents acting at imidazole receptors. Journal of Cerebral Blood Flow and Metabolism 1992; 12: 53–63
   PubMed Web of Science ®Google Scholar
• Meldrum B. S. Implications for neuroprotective treatments. Progress in Brain Research 2002; 135: 487–495
   PubMedGoogle Scholar
• Michaelis M. L. Drugs targeting Alzheimer's disease: Some things old and some things new. The Journal of Pharmacology and Experimental Therapeutics 2003; 304: 897–904
   PubMed Web of Science ®Google Scholar
• Milhaud D., Fagni L., Bockaert J., Lafon-Cazal M. Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures. Neuropharmacology 2000; 39: 2244–2254
   PubMedGoogle Scholar
• Montoliu C., Llansola M., Monfort P., Corbalan R., Fernandez-Marticorena I., Hernandez-Viadel M. L., et al. Role of nitric oxide and cyclic GMP in glutamate-induced neuronal death. Neurotoxicity Research 2001; 3: 179–188
   PubMedGoogle Scholar
• Olmos G., DeGregorio-Rocasolano N., Paz Regalado M., Gasull T., Assumpcio-Boronat M., Trullas R., et al. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. British Journal of Pharmacology 1999; 127: 1317–1326
   PubMed Web of Science ®Google Scholar
• Ozog M. A., Wilson J. X., Dixon S. J., Cechetto D. F. Rilmenidine elevates cytosolic free calcium concentration in suspended cerebral astrocytes. Journal of Neurochemistry 1998; 71: 1429–1435
   PubMed Web of Science ®Google Scholar
• Penner S. B., Smyth D. D. Central and renal I1 imidazoline preferring receptors: Two unique sites mediating natriuresis in the rat. Cardiovascular Drugs and Therapy 1994; 8: 43–48
   PubMedGoogle Scholar
• Pérez-Otaño I., Ehlers M. D. Learning from NMDA receptor trafficking: Clues to the development and maturation of glutamatergic synapses. Neurosignals 2004; 13(4)175–189
   PubMedGoogle Scholar
• Reis D. J., Regunathan S., Golanov E. V., Feinstein D. L. Protection of focal ischemic infarction by rilmenidine in the animal: Evidence that interactions with central imidazoline receptors may be neuroprotective. The American Journal of Cardiology 1994; 74: 25A–30A
   Google Scholar
• Surprenant A., Horstman D. A., Akbarali H., Limbird L. E. A point mutation of alpha 2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science 1992; 257: 977–980
   PubMedGoogle Scholar
• Talke P., Bickler P. E. Effects of dexmetedomide on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology 1996; 85: 551–557
   PubMed Web of Science ®Google Scholar
• Wahl A. S., Buchthal B., Rode F., Bomholt S. F., Freitag H. E., Hardingham G. E., et al. Hypoxic/ischemic conditions induce expression of the putative pro-death gene Clca1 via activation of extrasynaptic N-methyl-d-aspartate receptors. Neuroscience 2009; 158(1)344–352
   PubMedGoogle Scholar
• Xu J., Wojcik W. J. Gamma aminobutyric acid B receptor-mediated inhibition of adenylate cyclase in cultured cerebellar granule cells: Blockade by islet-activating protein. Journal of Pharmacology 1986; 239: 568–573
   Google Scholar
• Zhang Y. Clonidine preconditioning decreases infarct size and improves neurological outcome from transient forebrain ischemia in the rat. Neuroscience 2004; 125: 625–631
   PubMed Web of Science ®Google Scholar